Detalles de la búsqueda
1.
Pemetrexed plus dendritic cells as third-line therapy for metastatic esophageal squamous cell carcinoma.
Onco Targets Ther
; 9: 3901-6, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27418834
2.
MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations.
Transl Res
; 170: 1-7, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26687391
3.
Tumour Necrosis Factor-α Gene Polymorphism Is Associated with Metastasis in Patients with Triple Negative Breast Cancer.
Sci Rep
; 5: 10244, 2015 Jul 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-26165253
4.
Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer.
J Immunother
; 37(4): 250-5, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24714359
5.
Pemetrexed plus dendritic cells as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer who had treatment with TKI.
Med Oncol
; 31(8): 63, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24958515
6.
Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment.
Med Oncol
; 30(2): 550, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23576138
7.
Famitinib in metastatic renal cell carcinoma: a single center study.
Chin Med J (Engl)
; 126(22): 4277-81, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24238512
Resultados
1 -
7
de 7
1
Próxima >
>>